STADA is headquartered in Germany. — Photo provided by the agency

The pharmaceutical company STADA is expanding its consumer healthcare business in the Asia-Pacific region with the acquisition of Nizoral cream from Janssen Pharmaceutica NV, a Johnson & Johnson company.

The product, with the active ingredient ketoconazole, is indicated for the treatment of fungal skin infections.

Under the terms of the agreement, STADA acquires the existing distribution and Nizoral cream business in the markets including Việt Nam, the Philippines and Thailand as well as the trademark rights (TM) in Hong Kong, Australia, Indonesia, Malaysia, New Zealand and Singapore.

STADA EVP Stephane Jacqmin Emerging Market said: “We are delighted to take this important step of expansion in the Asia-Pacific region. This partnership further strengthens STADA´s role as a partner of choice in consumer healthcare.”

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 115 countries.

In the financial year 2023, STADA achieved group sales of over 3.73 billion euros and reported earnings before interest, taxes, depreciation and amortisation (EBITDA) of 802.1 million euros. — VNS